SG11201808849TA - Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative - Google Patents

Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Info

Publication number
SG11201808849TA
SG11201808849TA SG11201808849TA SG11201808849TA SG11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA SG 11201808849T A SG11201808849T A SG 11201808849TA
Authority
SG
Singapore
Prior art keywords
box
rehovot
international
science
york
Prior art date
Application number
SG11201808849TA
Inventor
Avigdor Scherz
Yoram Salomon
Liiach Agemy
Rachel Hamri
Dina Preise
Kwanghee Kim
Jonathan Coleman
Original Assignee
Yeda Res & Dev
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Memorial Sloan Kettering Cancer Center filed Critical Yeda Res & Dev
Publication of SG11201808849TA publication Critical patent/SG11201808849TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization International Bureau .. .... ..Yejd 11M11111011101 1111111111010111110111010111110111111101100111111111110111111 (10) International Publication Number .... ..or::,,, (43) International Publication Date WO 2017/179053 Al 19 October 2017(19.10.2017) WIPO I PCT (51) International Patent Classification: (US). COLEMAN, Jonathan; c/o Memorial Sloan-Ketter- A61K 45/06 (2006.01) A61K 31/7068 (2006.01) ing Cancer Center, 1275 York Avenue, Box 524, New A61K 31/409 (2006.01) A61K 31/7135 (2006.01) York, New York 10065 (US). A61K 31/675 (2006.01) A61P 35/00 (2006.01) (74) Agents: BEN-AMI, Paulina et al.; BEN-AMI & ASSOCI- (21) International Application Number: ATES, P.O Box 94, 7610002 Rehovot (IL). PCT/IL2017/050440 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: 10 April 2017 (10.04.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (26) Publication Language: English HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: 62/320,549 10 April 2016 (10.04.2016) US MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (71) Applicants: YEDA RESEARCH AND DEVELOP- MENT CO. LTD. [IL/IL]; at the Weizmann Institute of RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, T H, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Science, P.O. Box 95, 7610002 Rehovot (IL). MEMORI- AL SLOAN-KETTERING CANCER CENTER (84) Designated States (unless otherwise indicated, for every [US/US]; 1275 York Avenue, Box 524, New York, New York 10065 (US). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors: SCHERZ, Avigdor; 4 Tor Ha'aviv St., 7632104 Rehovot (IL). SALOMON, Yoram; c/o Yeda Research and Development Co. Ltd., Weizmann Institute of Science, P.O. Box 95, 7610002 Rehovot (IL). AGEMY, Lilach; c/o Yeda Research and Development Co. Ltd., Weizmann Institute of Science, P.O. Box 95, 7610002 Re- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). hovot (IL). HAMRI, Rachel; c/o Yeda Research and De- Published: velopment Co. Ltd., Weizmann Institute of Science, P.O. — with international search report (Art. 21(3)) Box 95, 7610002 Rehovot (IL). PREISE, Dina; c/o Yeda Research and Development Co. Ltd., Weizmann Institute — before the expiration of the time limit for amending the of Science, P.O. Box 95, 7610002 Rehovot (IL). KIM, Kwanghee; c/o Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 524, New York, New York 10065 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) Il M ir) 0 01 IN Il IN 1-1 (54) Title: COMBINATIONAL THERAPIES FOR TREATMENT OF CANCER COMPRISING A BACTERIOCHLOROPHYLL ei C:::: ) DERIVATIVE r .- (57) : An anti-myeloid-derived suppressor cells agent (\"anti-MDSCs agent\") and a bacteriochlorophyll derivative (herein - ,7 1 ,1 9 after \"Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequen - .,. tially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
SG11201808849TA 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative SG11201808849TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Publications (1)

Publication Number Publication Date
SG11201808849TA true SG11201808849TA (en) 2018-11-29

Family

ID=58794130

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808849TA SG11201808849TA (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Country Status (14)

Country Link
US (2) US11278555B2 (en)
EP (1) EP3442582A1 (en)
JP (2) JP2019510807A (en)
KR (2) KR20190008206A (en)
CN (1) CN109862918A (en)
AU (2) AU2017250732B2 (en)
BR (1) BR112018070847A2 (en)
CA (1) CA3020067A1 (en)
IL (1) IL262191A (en)
MX (2) MX2018012392A (en)
RU (2) RU2747258C2 (en)
SG (1) SG11201808849TA (en)
WO (1) WO2017179053A1 (en)
ZA (1) ZA201807187B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
JP6609626B2 (en) 2014-05-30 2019-11-20 デイコ アイピー ホールディングス，エルエルシー Vacuum generation system with ejector, pneumatic control valve and selective aspirator
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2022149934A1 (en) * 2021-01-08 2022-07-14 가톨릭대학교 산학협력단 Antibody-polyethylene glycol-photosensitizer conjugate for anticancer immunotherapy of cancer cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1137411T3 (en) 1998-12-09 2007-03-26 Yeda Res & Dev Palladium-substituted bacterial chlorophyll derivatives and their use
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
CA2661319C (en) 2006-08-23 2015-12-01 Yeda Research And Development Co. Ltd Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
BRPI0920108A2 (en) 2008-10-23 2016-12-13 Steba Biotech N V cyclic peptidomimetic containing argin, glycine, aspartic acid (rgd), cyclic peptidomimetic conjugate containing rgd, pharmaceutical composition, conjugate and use thereof.
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
TWI442945B (en) * 2011-05-18 2014-07-01 Univ Nat Taiwan Methods of using dual-effect liposome in therapy
WO2014141289A1 (en) * 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
MX2022003190A (en) 2022-04-11
KR20190008206A (en) 2019-01-23
AU2017250732A1 (en) 2018-11-15
RU2747258C2 (en) 2021-04-29
US11278555B2 (en) 2022-03-22
CN109862918A (en) 2019-06-07
AU2023200591A1 (en) 2023-03-09
CA3020067A1 (en) 2017-10-19
US20220202838A1 (en) 2022-06-30
JP2022031823A (en) 2022-02-22
EP3442582A1 (en) 2019-02-20
KR20220139445A (en) 2022-10-14
ZA201807187B (en) 2020-01-29
US20190125769A1 (en) 2019-05-02
RU2018139523A3 (en) 2020-07-07
IL262191A (en) 2018-11-29
AU2017250732B2 (en) 2022-11-10
BR112018070847A2 (en) 2019-02-05
JP2019510807A (en) 2019-04-18
RU2018139523A (en) 2020-05-15
RU2021110230A (en) 2021-05-26
WO2017179053A1 (en) 2017-10-19
MX2018012392A (en) 2019-08-21

Similar Documents

Publication Publication Date Title
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201808125RA (en) Methods for solid tumor treatment
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201908391XA (en) Methods for modulating an immune response
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201808849TA (en) Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
SG11201807982UA (en) Substituted inhibitors of menin-mll and methods of use
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201407340YA (en) Treatment of myelosuppression
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201808762XA (en) Diagnostic methods for patient specific therapeutic decision making in cancer care
SG11201804360XA (en) Mat2a inhibitors for treating mtap null cancer
SG11201811237WA (en) Combination therapies
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer